ReviewOncology research2025
A Review on Novel Applications of Nanoparticles in Pediatric Oncology.
Review in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomedicine has evolved significantly over the last decades and expanded its applications in pediatric oncology, which represents a special domain with unique patients and distinct requirements. Τhe need for early cancer diagnosis and more effective and targeted therapies aiming to increase the pediatric patients' survival rates and minimize the treatment-related side effects to survivors is profound. Nanoparticles (NPs) come as a beacon of hope to provide sensitive cancer diagnostic tools and assist contrast agents' transport to the malignant tumors. Besides, NPs could be designed to deliver targeted drugs and genes to tumors, minimizing the medicine-related toxicities. Metal and metal oxide NPs could be exploited as sensitizers to enhance chemotherapy and radiotherapy effects. Future research should emphasize pediatric models to gain secure results about NPs' safety and efficiency for pediatric cancer patients. This review presents the recent studies on the use of NPs in pediatric cancer management and highlights their impact on diagnosis, treatment outcomes, and the quality of life of the survivors. The purpose of this study is to investigate the benefits that may arise from the use of NPs in pediatric oncology, address the potential limitations and challenges, and discuss the needs for future research efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.